The Business of Biofabrication

Introduction

Cellino and Matricelf have announced a global collaboration aimed at advancing personalized treatments for spinal cord injuries. The partnership brings together innovative biomanufacturing and regenerative techniques to develop scalable, patient-specific therapies.

Partnership Overview

The collaboration leverages Cellino’s Nebula™ technology—an automated, closed-cassette system for producing high-quality induced pluripotent stem cells (iPSCs)—and Matricelf’s proprietary double autologous 3D differentiation process. This union is designed to accelerate the development and commercialization of regenerative therapies for spinal cord injuries.

Technological Innovation

Cellino’s Nebula™ system ensures on-demand, contamination-free iPSC production with unparalleled consistency and sterility. In parallel, Matricelf employs an extracellular matrix-based hydrogel derived from the patient’s own tissue to facilitate precise cell differentiation, enabling the formation of functional neural tissue without the need for immunosuppression.

Milestones Achieved

A significant milestone in this collaboration was the successful manufacturing and delivery of autologous iPSC lines from four donors by Cellino. Matricelf then transformed these iPSCs into neural tissues that exhibited synchronized electrical activity, a key indicator of functional neural networks. These outcomes were validated through rigorous industry-standard assays assessing genetic and protein neural marker expressions.

Future Plans

Building on these promising results, Matricelf plans to file an Investigational New Drug (IND) application next year to launch clinical trials. This initiative aims to address the urgent unmet need in spinal cord injury treatments and has the potential to restore function for millions of patients worldwide.

Company Profiles

About Cellino

Cellino is at the forefront of advanced biomanufacturing technology. Specializing in the production of personalized cell, tissue, and organ replacements, the company is committed to bringing regenerative medicine closer to real-world clinical applications. Through its innovative Nebula™ technology, Cellino offers automated and scalable iPSC production, ensuring high quality, consistency, and sterility for personalized therapies.

About Matricelf

Matricelf is a biotechnology company dedicated to developing transformative regenerative therapies, particularly for spinal cord injuries. The company’s approach involves a double autologous 3D differentiation process and the use of extracellular matrix-based hydrogels derived from a patient’s own tissues. This methodology facilitates precise cell differentiation and tissue formation, aiming to eliminate the need for immunosuppression while advancing patient-specific neural regeneration.